J&J-Johnson & Johnson (JNJ) Laps the Stock Market: Here's Why

Company Performance - Johnson & Johnson (JNJ) closed at $157.89, reflecting a +1.87% change from the previous session, outperforming the S&P 500's gain of 0.24% [1] - Over the past month, JNJ shares increased by 4.62%, surpassing the Medical sector's gain of 3.63% and the S&P 500's gain of 2.37% [1] Upcoming Financial Results - The company is expected to report an EPS of$ 2.59, indicating a 4.43% decline year-over-year, with projected net sales of $21.66 billion, up 1.29% from the previous year [2] - For the annual period, earnings are anticipated to be$ 10.58 per share and revenue at $90.03 billion, reflecting increases of +6.01% and +1.36% respectively from last year [3] Analyst Estimates and Rankings - Recent modifications to analyst estimates for JNJ are crucial as they reflect short-term business trends, with positive revisions indicating analyst optimism [4] - The Zacks Rank system, which integrates estimate changes, currently ranks JNJ at 3 (Hold), with a consensus EPS projection that has moved 1% higher in the past 30 days [6] Valuation Metrics - JNJ has a Forward P/E ratio of 14.65, which is higher than the industry average of 12.51 [7] - The company also has a PEG ratio of 2.49, compared to the Large Cap Pharmaceuticals industry's average PEG ratio of 1.35 [8] Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, holds a Zacks Industry Rank of 174, placing it in the bottom 31% of over 250 industries [9]